|Articles|March 16, 2021
- BioPharm International-03-15-2021
- Volume 2021 eBook
- Issue 1
Can FDA Reinvent Inspections?
Author(s)Agnes Shanley
A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?
Advertisement
Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.
Article details
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4–5
Citation
When referring to this article, please cite it as: A. Shanley, "Can FDA Reinvent Inspections, BioPharm International Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 4 years ago
It Takes a Bio/Pharma Villageover 4 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 4 years ago
Growing Pipeline of Antisense Oligonucleotides Prompts Guidanceover 4 years ago
Gene Therapies Target Neurodegenerative Diseasesover 4 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 4 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 4 years ago
Regulatory and Standard Setting Organizations DirectoryNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
